Drug Trial Radar · NCT00977080
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Last checked: Nov 19, 2026Latest source record: Jun 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Nov 2009
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Sep 15, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
Conditions
- Chronic Kidney Disease
- Secondary Hyperparathyroidism
- Hemodialysis
Interventions
ParicalcitolDrug
Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
CinacalcetDrug
On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants Who Achieve a Mean Intact Parathyroid Hormone (iPTH) Value Between 150 to 300 pg/mL During the Evaluation Period (Weeks 21 to 28).Time frame: Weeks 21 to 28
Locations
83 sites in 12 countries. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 22781
Tempe, Arizona
Site Reference ID/Investigator# 24342
Chula Vista, California
Site Reference ID/Investigator# 21142
Los Angeles, California
Site Reference ID/Investigator# 22762
Los Angeles, California
Site Reference ID/Investigator# 22758
Riverside, California
Site Reference ID/Investigator# 21442
San Diego, California
Site Reference ID/Investigator# 23688
Arvada, Colorado
Site Reference ID/Investigator# 21370
Coral Springs, Florida
Site Reference ID/Investigator# 25902
Hudson, Florida
Site Reference ID/Investigator# 21146
Lauderdale Lakes, Florida
Site Reference ID/Investigator# 26743
Lauderdale Lakes, Florida
Site Reference ID/Investigator# 22788
Miami, Florida
Site Reference ID/Investigator# 22722
Orlando, Florida
Site Reference ID/Investigator# 23147
Tampa, Florida
Site Reference ID/Investigator# 22778
Meridian, Idaho
Site Reference ID/Investigator# 21369
Detroit, Michigan
Site Reference ID/Investigator# 22786
Detroit, Michigan
Site Reference ID/Investigator# 21144
St Louis, Missouri
Site Reference ID/Investigator# 21443
St Louis, Missouri
Site Reference ID/Investigator# 21145
Omaha, Nebraska
Site Reference ID/Investigator# 22505
Flushing, New York
Site Reference ID/Investigator# 22759
Toledo, Ohio
Site Reference ID/Investigator# 22796
Lancaster, Pennsylvania
Site Reference ID/Investigator# 22770
Philadelphia, Pennsylvania
Site Reference ID/Investigator# 22772
Aiken, South Carolina
Site Reference ID/Investigator# 21147
Orangeburg, South Carolina
Site Reference ID/Investigator# 22982
Houston, Texas
Site Reference ID/Investigator# 21143
Houston, Texas
Site Reference ID/Investigator# 22506
San Antonio, Texas
Site Reference ID/Investigator# 22776
Bluefield, West Virginia
Site Reference ID/Investigator# 22311
Brno, Czechia
Site Reference ID/Investigator# 22310
Jilemnice, Czechia
Site Reference ID/Investigator# 21624
Ústí nad Labem, Czechia
Site Reference ID/Investigator# 22363
Aalborg, Denmark
Site Reference ID/Investigator# 23105
Copenhagen, Denmark
Site Reference ID/Investigator# 23909
Fredericia, Denmark
Site Reference ID/Investigator# 22462
Holstebro, Denmark
Site Reference ID/Investigator# 21748
Coburg, Germany
Site Reference ID/Investigator# 33268
Darmstadt, Germany
Site Reference ID/Investigator# 35903
Düsseldorf, Germany
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.